Clinical Trials on Human Immunodeficiency Virus Infections in United States

Total 8918 results

ViiV Healthcare
GlaxoSmithKline

Completed

A Study to Assess the Relative Bioavailability of Tablet Formulations of GSK2248761 in Healthy Adult Subjects. SGN114435

Infection, Human Immunodeficiency Virus | Infections, Human Immunodeficiency Virus and Herpesviridae

United States
MacroGenics
National Institute of Allergy and Infectious Diseases (NIAID); National Institutes... and other collaborators

Active, not recruiting

A Study of MGD020 Alone or Combined With MGD014 in Persons With HIV-1 on Antiretroviral Therapy

Human Immunodeficiency Virus I Infection | Immunodeficiency Virus Type 1, Human | Human Immunodeficiency Virus Type 1

United States
M.D. Anderson Cancer Center

Completed

Attitudes and Beliefs and the Steps of HIV Care

Human Immunodeficiency Virus Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

Dose, Safety, Tolerability, and Immunogenicity of an HIV-1 Vaccine, VRC-HIVRGP096-00-VP, With Alum in Healthy Adults

Human Immunodeficiency Virus (HIV) | Human Immunodeficiency Virus Prevention

United States
ViiV Healthcare

Completed

Relative Bioavailability Study of Phase III Tablet Formulation of Cabotegravir

Infection, Human Immunodeficiency Virus

United States
GlaxoSmithKline

Completed

A Study To Evaluate Formulations And Food Effect On GSK364735 In Healthy Subjects.

HIV Infection | Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline; Shionogi

Completed

Healthy Volunteer Study To Assess The Bioavailability of GSK1265744 When Administered Orally Either When Fasted or Following a Meal.

HIV Infection | Infection, Human Immunodeficiency Virus

United States
University of Pennsylvania
National Institute of Mental Health (NIMH)

Completed

Being Responsible for Ourselves HIV Risk Reduction for Black MSM (BRO)

Sexually Transmitted Disease (STD) | Human Immunodeficiency Virus Infection (HIV)

United States
ViiV Healthcare
GlaxoSmithKline; Shionogi

Completed

Drug Interaction Study Between GSK1349572 and Tipranavir/Ritonavir in Healthy Volunteers (ING)

HIV Infections | Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline

Completed

Bioequivalence Study of a Fixed-dose Combination (FDC) of Dolutegravir (DTG) and Rilpivirine (RPV)

HIV Infections | Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline

Terminated

A Study to Evaluate the Pharmacokinetics of an Oral Contraceptive When Co-administered With GSK2248761 in Healthy Adult Female Subjects.

HIV Infections | Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline

Completed

Drug-drug Interaction (DDI) Rifabutin

Infection, Human Immunodeficiency Virus

United States
GlaxoSmithKline

Completed

GSK706769 Repeat Dose Study

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare

Completed

A Study of the Relative Bioavailability of BMS-626529 Administered as BMS-663068 From 150mg Low-dose Extended-release Tablets Compared to 600mg Reference Extended-release Tablets in Healthy Subjects

Infection, Human Immunodeficiency Virus

United States
GlaxoSmithKline

Completed

A Two-part Study to Compare a Tablet and Capsule Formulation of GSK2838232 With and Without Food, and to Assess the Safety and Drug Levels of Repeated Once-daily Doses of GSK2838232 Without Ritonavir

HIV Infections | Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline

Completed

Bioequivalence Study of Fixed Dose Versus Single Entities of Dolutegravir and Lamivudine

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline

Completed

Single-dose Pharmacokinetics of BMS-626529, Administered as BMS-663068, in Subjects With Hepatic Impairment Compared to Healthy Subjects

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
Glaxosmithkline/Quintiles

Completed

A Study to Evaluate the Effect of High Fat Meal on Cabotegravir

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline; Janssen Pharmaceuticals

Completed

Relative Oral Bioavailability Study of Different Fixed Dose Combinations of Dolutegravir and Rilpivirine in Healthy Subjects

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline

Completed

Effect of Rifampin (RIF) on the Pharmacokinetics (PK) of Oral Cabotegravir (CAB) in Healthy Subjects

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline

Completed

Bioavailability Study of a Dolutegravir Dispersible Tablet and Effect of Different Types of Water on the Dispersible Tablet in Healthy Volunteers

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline

Completed

Study to Evaluate the Effect of GSK1265744 on Cardiac Conduction

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline

Completed

Study to Evaluate the Drug Interaction Between Dolutegravir (DTG) and Daclatasvir (DCV) in Healthy Adult Subjects

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline

Completed

A Randomized Study to Assess the Relative Bioavailability of New Formulations of GSK1265744 Long Acting Parental (LAP) in Healthy Adult Subjects

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline

Completed

Effect of Carbamazepine on Dolutegravir Pharmacokinetics in Healthy Adult Subjects

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline; Shionogi

Completed

Drug Interaction Study Between Dolutegravir and Prednisone

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline; Shionogi

Completed

Relative Bioavailability Study of Two New Dolutegravir/Abacavir/Lamivudine Fixed Dose Combination Tablets

Healthy Subjects | Infection, Human Immunodeficiency Virus

United States
GlaxoSmithKline

Completed

DDI Study of Etravirine and GSK1265744

Healthy Subjects | Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline

Completed

A Study to Assess Relative Bioavailability and Food Effect of New Formulations of GSK2248761

HIV Infections | Infection, Human Immunodeficiency Virus

United States
GlaxoSmithKline

Completed

Safety and Efficacy Study of GSK2838232 in Human Immunodeficiency Virus (HIV)-1 Infected Adults

HIV Infections | Infection, Human Immunodeficiency Virus

United States, Canada
George Washington University

Completed

Immune Response to Seasonal Influenza Vaccine in HIV Infected Individuals

Influenza, Human | Human Immunodeficiency Virus I Infection

United States
ViiV Healthcare

Completed

Pharmacokinetic Study of Cabotegravir Long-acting in Healthy Adult Volunteers

HIV Infections | Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline

Completed

A Study to Assess the Effect of High Fat Meal and Increased Gastric pH on the Bioavailability of an Extended Release Formulation of BMS-663068 in Healthy Subjects

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline

Completed

GSK1349572 Relative Bioavailability Study

Infection, Human Immunodeficiency Virus

United States
GlaxoSmithKline

Terminated

A Single Dose Pharmacokinetic (PK) and Safety Study of GSK2838232 With and Without Ritonavir (RTV) Conducted in Healthy Subjects

Infection, Human Immunodeficiency Virus

United States
GlaxoSmithKline

Completed

Single Dose Escalation Study of GSK2838232 in Healthy Subjects

Infection, Human Immunodeficiency Virus

United States
GlaxoSmithKline

Terminated

A Repeat Dose Pharmacokinetic (PK) and Safety Study of GSK2838232 With and Without Ritonavir (RTV) Conducted in Healthy Subjects

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline

Withdrawn

A Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C-GSK2248761 Administered as an Oral Suspension to Healthy Adult Subjects

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline; Shionogi

Completed

Drug Interaction Study Between Dolutegravir and an Oral Contraceptive Containing Norgestimate and Ethinylestradiol

Infection, Human Immunodeficiency Virus

United States
GlaxoSmithKline

Completed

A Drug Interaction Study Between Simvastatin, Atorvastatin, Rosuvastatin, and GSK2248761 in Healthy Subjects.

Infection, Human Immunodeficiency Virus

United States
Fred Hutchinson Cancer Center
University of Washington

Completed

MMF for HIV Reservoir Reduction

Human Immunodeficiency Virus I Infection

United States
ViiV Healthcare
GlaxoSmithKline

Terminated

A Study to Determine the Effect of Multiple Doses of BMS-955176 on the Electrocardiograph of Healthy Subjects

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline; Shionogi

Completed

Phase 1, Open Label, Two Arm, Fixed Sequence Study to Evaluate the Effect of Rifampin and Rifabutin on GSK1349572 Pharmacokinetics in Healthy Male and Female Volunteers

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline; Shionogi

Completed

A Study to Evaluate the Effect of Boceprevir and Telaprevir on Dolutegravir Pharmacokinetics in Healthy Adult Subjects (ING115697).

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline

Completed

A Study to Evaluate the Effect of BMS-955176 on Pharmacokinetics of Dolutegravir and the Effect of Dolutegravir on the Pharmacokinetics of BMS-955176

Infection, Human Immunodeficiency Virus

United States
GlaxoSmithKline

Completed

Single and Repeated Dose Escalation Study of GSK2838232

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline

Completed

Pharmacokinetics, Safety and Tolerability Study of Abacavir/ Dolutegravir/ Lamivudine Fixed-dose Combination Tablets in Healthy Japanese Subjects

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline; Shionogi

Completed

Dolutegravir Renal Impairment Study

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline; Shionogi

Completed

A Study to Investigate the Pharmacokinetics, Safety and Tolerability of GSK1349572 (Dolutegravir, DTG) in Healthy Japanese Subjects

Infection, Human Immunodeficiency Virus

United States
GlaxoSmithKline

Completed

Drug Interaction Study of Darunavir/Ritonavir and Lopinavir/Ritonavir on GSK2248761 PK and CYP450 Probe Drugs

Healthy Subjects | Infection, Human Immunodeficiency Virus

United States

Clinical Trials on Human Immunodeficiency Virus Infections in United States

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Costa Rica

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations